Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Roger's 1998 Short Picks -- Ignore unavailable to you. Want to Upgrade?

To: Pancho Villa who wrote (11536)	7/15/1998 9:00:00 AM
From: poodle	Read Replies (1) \| Respond to of 18691

ZONA: Zonagen Files NDA for Vasomax Business Wire - July 15, 1998 08:45 THE WOODLANDS, Texas--(BW HealthWire)--July 15, 1998--Zonagen Inc. (NASDAQ:ZONA)(Pacific:ZNG) today announced that the company has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for its lead product, Vasomax(R). The indication to be pursued is for the treatment of male erectile dysfunction (MED). Zonagen and Schering-Plough Corporation (NYSE:SGP) signed a worldwide marketing agreement in November 1997 for Vasomax(R) in this indication.